Daily Brief
Thursday signal: Israel's compounding structural strains
The central bank's warning of permanently slower growth and a fragile power grid expose the domestic cost of prolonged conflict, even as local tech remains a global anchor — press a signal for coverage.
World
Washington bypassed Israel to advance its own Gulf energy strategy — leaving Jerusalem scrambling to halt a potential Saudi nuclear weapons program.
BackgroundA 123 agreement is a US statutory framework required for bilateral civil nuclear trade to prevent weapons proliferation. Prior diplomatic efforts sought to condition such technology transfers on Riyadh establishing formal ties with Jerusalem.
- The new bilateral safeguards agreement omits the strictest nonproliferation standards, enabling Saudi Arabia to enrich uranium on its own soil.
- Israeli political leaders called the deal a severe strategic failure and are urging aggressive lobbying to convince the US Congress to block the pact.
- US congressional Democrats are already preparing a joint resolution to oppose the deal, citing the risk of further proliferation across the Middle East.
Tech
Even the most trusted security perimeter tools are vulnerable to administrative bypass — forcing enterprises to strictly isolate management interfaces from the public web.
BackgroundCheck Point is an Israel-headquartered pioneer in network security whose software protects major global corporations and government agencies. Zero-day exploits are software vulnerabilities that are discovered and used by attackers before developers can issue a patch.
- The vulnerability, tracked as CVE-2026-16232, allows remote attackers to bypass authentication and obtain administrative login tokens, exposing private corporate environments to total takeover.
- The US Cybersecurity and Infrastructure Security Agency added the vulnerability to its catalog of known exploits, warning of active attacks and giving agencies until mid-August to apply the hotfix.
- The company confirmed that the exploit was used against a small number of customers who exposed their administrative ports to the internet, underscoring the risk of poor network hygiene.
Startup
Glow's mega-round proves that venture capital is consolidating around elite Israeli security founders — validating autonomous AI agents as the next frontier in endpoint protection.
BackgroundSecuring corporate endpoints has become increasingly difficult as employees introduce unapproved generative AI tools and plugins into their workflows. Glow was founded in Tel Aviv and Palo Alto by former senior executives from Meta, Snowflake, and Claroty.
- The funding includes a massive Series B round led by Sequoia Capital, Cyberstarts, Greenoaks, and Redpoint Ventures, showing continued investor appetite for cyber.
- Glow’s software deploys autonomous AI agents to continuously map workplace devices, identifying vulnerabilities in real time to automatically isolate and remove unapproved applications.
- The company's rapid ascent to a billion-dollar valuation within a year validates Israel's startup ecosystem as a primary source for critical AI-era security infrastructure.
Science
Weizmann’s approach shifts the Alzheimer’s fight from plaque clearing to immune system rejuvenation — offering a safer, systemic alternative to traditional amyloid treatments.
BackgroundTraditional Alzheimer's drugs target the direct accumulation of amyloid plaques in the brain, often with mixed clinical results. This new approach instead modulates the body's immune system to combat age-related decline and reduce chronic neuroinflammation.
- The monoclonal antibody, IBC-Ab002, developed by Weizmann-linked biotech ImmunoBrain, was tested on 40 patients across three European countries, representing the first human safety hurdle for the platform.
- The trial demonstrated that targeting the PD-1/PD-L1 pathway helps the body's own immune cells clear toxic proteins, validating a novel mechanism that bypasses direct plaque-clearing strategies.
- The successful safety profile directly clears the drug for Phase 2 efficacy trials, allowing researchers to measure cognitive preservation in a larger cohort of patients next year.
Business
Markets
Economy
Politics
Health
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.